<DOC>
	<DOC>NCT01495741</DOC>
	<brief_summary>This study will assess asenapine (Sycrest速) use in participants with bipolar disorder; comparison will be made to the use of risperidone (RISPERDAL速CONSTA速) and olanzapine (Zyprexa速). The occurrence of identified and potential clinically important risks will also be assessed.</brief_summary>
	<brief_title>Post-Authorization Safety Surveillance Study of Asenapine in Participants With Bipolar Disorder (P08307)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Inclusion Criteria for the Bipolar Disease Cohort: A diagnosis of Bipolar Disorder Exclusion Criteria for the Bipolar Disease Cohort: Inclusion Criteria for the potential Schizophrenia Cohort: A diagnosis of schizophrenia Exclusion Criteria for the potential Schizophrenia Cohort: A prior and/or concomitant diagnosis of bipolar disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Mania</keyword>
	<keyword>Manic</keyword>
	<keyword>Depressive</keyword>
	<keyword>Manic Depressive</keyword>
</DOC>